Urine testing to skip repeated NTM sputum checks in cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at whether a urine test (instead of repeated sputum—mucus—from the lungs testing) can help determine who with cystic fibrosis does not have certain lung germs called NTM. If the urine test works, it could reduce the need for lung sample testing while still keeping people safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give informed consent (online or in person)
- You are enrolled in the Cystic Fibrosis Foundation Patient Registry (CFFPR)
- You can follow the study steps that fit with your usual clinic care
- You have cystic fibrosis and recent culture results showing no NTM (based on at least one negative culture in the last year, and no past known positive NTM cultures)
- A study doctor must agree there’s no other medical issue that would make participation unsafe or confuse the results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
This study tests if people with cystic fibrosis can collect sputum samples at home and mail them in, instead of coming to the clinic. It aims to make participation easier for patients.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
This study looks at how highly effective CF modulator therapies change the bacteria living in the lungs of people with cystic fibrosis. Understanding these changes may help improve future treatments.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.